NCT03943602 (CaboPen) is a Phase 2 clinical trial of Cabozantinib in Penile Squamous Cell Carcinoma, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

Who is sponsoring NCT03943602?

NCT03943602 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

What drugs are being tested in NCT03943602?

Interventions in NCT03943602: Cabozantinib.

What condition does NCT03943602 study?

NCT03943602 studies Penile Squamous Cell Carcinoma.

Is NCT03943602 still recruiting?

NCT03943602 is currently status unknown. Last updated 25 February 2021.

Last reviewed 2021-02-25 · How we verify

NCT03943602: CaboPen

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Status unknown Phase 2 Last updated 25 February 2021

What this trial tests

Phase 2 trial testing Cabozantinib in Penile Squamous Cell Carcinoma in 37 participants. Status unknown.

Timeline

1 August 2019

Primary endpoint
1 June 2022

1 September 2022

Quick facts

Lead sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 August 2019
Primary completion	1 June 2022
Estimated completion	1 September 2022
Sites	1 location across Italy

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Penile Squamous Cell Carcinoma — all drugs for Penile Squamous Cell Carcinoma →

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →

Who can join

Adults 18 to 75, male only, with Penile Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature.
Stecca CE, Alt M, Jiang DM, Chung P, et al · · 2021 · cited 31× · PMID 33454930 · DOI 10.1007/s40487-020-00135-z
Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy.
Benjamin DJ, Hsu RC. · · 2024 · cited 2× · PMID 39882447 · DOI 10.3389/fonc.2024.1457006

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Penile Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT06353906 — Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer · Phase 2 · recruiting
NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
NCT02496208 — Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · Phase 1 · active not recruiting

Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials

Trials by the same sponsor.

NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
NCT06999824 — Revisiting the Concept of Nerve Sparing Radical Hysterectomy · not yet recruiting
NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03943602 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Last refreshed: 25 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing